Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

An RNA profile identifies two subsets of multiple sclerosis patients differing in disease activity.
IFN-β Treatment Requires B Cells for Efficacy in Neuroautoimmunity.
Epitope spreading as an early pathogenic event in pediatric multiple sclerosis.
The neurotoxicant, cuprizone, as a model to study demyelination and remyelination in the central nervous system.
BIIB033 single ascending dose study in healthy volunteer subjects
Viral triggers of multiple sclerosis.
Brief International Cognitive Assessment for MS (BICAMS): international standards for validation.
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis.
T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis.
Teriflunomide for multiple sclerosis.
Scientists probe strategies to repair neuron damage in multiple sclerosis.
Autoimmune tolerance eliminates relapses but fails to halt progression in a model of multiple sclerosis.
Gender as risk factor for autoimmune diseases.
Reduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelination.
Comparative pharmacogenetics of multiple sclerosis: IFN-β versus glatiramer acetate.
Primary progressive multiple sclerosis-why we are failing.
The pathology of acute disseminated encephalomyelitis produced experimentally in the rhesus monkey and its resemblance to human demyelinating disease.
Microglial/macrophage accumulation during cuprizone-induced demyelination in C57BL/6 mice.
Postpartum disease activity and breastfeeding in multiple sclerosis revisited.
Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis.
XVI European Charcot Foundation lecture: nutrition and environment, can MS be prevented?
Epigenetics in multiple sclerosis susceptibility: difference in transgenerational risk localizes to the major histocompatibility complex.
Direct immunomodulatory influence of IFN-β on human astrocytoma cells.
Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.
SMC Says Yes to Aubagio® (teriflunomide), a New Once Daily First-line Oral Treatment Available for People with an Active Relapsing Remitting Form of MS

Pages